Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
about
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy modelsImmunotherapeutic approaches for Alzheimer's diseaseThe release and trans-synaptic transmission of Tau via exosomesAffinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyThe intersection of amyloid beta and tau at synapses in Alzheimer's diseaseEpitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Novel immunological approaches for the treatment of Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathyPassive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathologyAntibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Tau passive immunization inhibits not only tau but also Aβ pathologyNovel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Tau immunotherapy and imaging.Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.Harnessing the immune system for treatment and detection of tau pathology.Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.Invited review: Drug development for tauopathies.Tau Immunotherapy.Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations.Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.Anti-tau antibody reduces insoluble tau and decreases brain atrophyGeneration and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approachTauopathies: Mechanisms and Therapeutic Strategies."Tau immunotherapy: Hopes and hindrances".Vaccination strategies in tauopathies and synucleinopathies.Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
P2860
Q27308146-9EF7F705-4CD3-4551-B862-B2BBC138727FQ28081278-40365843-95C8-4CE5-B893-0D9F50253D94Q28468594-F211AF1E-02C5-4BC2-926D-E350FAEEECE3Q30805841-1186C786-E7BA-4909-B477-32CF6E55C40BQ33559937-FBB64D81-3DA2-46A2-B42C-53A5BAEB880EQ33640390-F7D20501-0EA1-4390-9C78-D1E7BE35545CQ34054680-1C96D640-4E62-4689-8185-8DCCE63E14C0Q34205027-795CADB1-BD29-44FD-A9A1-8E36B99B784BQ34562675-08538C4B-C9A4-4076-813A-2DE48D08FDFBQ34664345-247FCB43-56F4-4F06-A26B-7298C8427FB9Q34973787-30AD6DEB-9CD2-4A12-B37B-D0FEFEBBB894Q35204878-F9DF2038-1909-470B-B90C-84C3E3EC059FQ35542169-CF6DA29C-7365-4E25-AC16-43A7AB78EA74Q35624263-5F402516-C6C3-4C64-87E5-6C155115DFD5Q35745135-37915372-AB80-4B24-B8A7-594C7F445B4DQ36395623-BFEFFA4D-6342-4E0B-A62E-4A7010EE8EB3Q36484413-248538E2-DBBB-46B0-91A6-CC25676AF0C4Q36558485-57F3C9A9-975A-4D57-8869-2CF161283433Q37311364-B8952E14-C339-4F05-B178-F522342DAB98Q37368709-D07BA532-86A5-4A37-93AE-257D95DC94A4Q37566888-C217756F-52FF-4049-812E-FD6C0E9C6A6CQ37579019-B55239F2-6B1B-47BF-8F58-398D3DC133B7Q37610545-BE3AA3CB-1EF5-460C-85A3-85CF1677D844Q38136880-85B7BD2F-6EAE-46F7-AA9B-5E1C9715F9CFQ38175453-B339E0B9-ED81-47D6-9B53-4AFD4AC7EFDBQ38194049-DB168B51-3D05-46EE-9306-816CA009F3C9Q38204620-99399AF2-A246-4082-9F8D-8131D4563EE0Q38263698-64139BE4-DDA3-40C6-B8D5-BB4E47D35EF3Q38628672-E6BCBDC8-7A30-4000-99C4-9FEDE1F07891Q38634954-EEF4F6E9-287A-4BD3-A093-0952313BCE4BQ38912261-EBEBF7A9-BAEF-46FE-8C9C-E04E2E183D5BQ40239437-06F16554-0EF4-4198-8C81-82BCCF8C32FFQ40854182-54747B1A-BD55-4345-B0AB-A809B5322B6FQ41150186-1610B47F-E2E1-457E-9ABF-0D79B0AE444BQ41196178-8D59BCBD-4494-4A91-8758-937EBF728782Q41629521-E2D4E82C-77AB-4445-889F-FD19A153000CQ47253592-8A73FFB4-17B1-4446-A4C5-4E4DF693C629Q47629452-7B2636D8-FC94-4583-891A-0BEDA1DB9460Q47860105-612E5036-BDBC-4FCC-83AF-2D8086BCCCB2Q48532697-6BBDA100-2678-4901-8D92-4A1A70C946B6
P2860
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@ast
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@en
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@nl
type
label
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@ast
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@en
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@nl
prefLabel
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@ast
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@en
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@nl
P2093
P2860
P1433
P1476
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity
@en
P2093
Christopher M Acker
Cristina d'Abramo
Heidy T Jimenez
Peter Davies
P2860
P304
P356
10.1371/JOURNAL.PONE.0062402
P407
P577
2013-04-29T00:00:00Z